Odronextamab combined with CHOP showed high efficacy in untreated DLBCL, with a 100% response rate at the 160 mg dose. The safety profile was manageable, with no new safety signals, and most patients ...

Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once touted as a future blockbuster – after it failed the Phase 3 CMVictory trial ...

As a result, we now expect the review time line to be extended into 2026 and be dependent upon positive Phase III efficacy results from our ongoing flu vaccine trial and the addition of these data to ...

Trump's marijuana rescheduling could strip DOT of testing authority for 4 million CDL drivers. Without a safety carve-out, ...

LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...

According to the Pan American Health Organization, 7 out of 10 deaths in people over 70 are from non-communicable diseases (NCDs). Aging itself is the single greatest risk factor for the majority of ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Megan Hilty will not perform Dec. 19 - 20, Dec. 21 at 2pm, Dec. 27 at 2pm, Jan. 3 at 2pm, and Jan. 6. Hilty's final performance will be Jan. 11, 2026. Jennifer Simard will not perform Jan. 6 - 11.